Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Down 5.8% – Here’s Why

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)’s stock price was down 5.8% during mid-day trading on Thursday . The stock traded as low as $21.00 and last traded at $21.03. Approximately 218,859 shares traded hands during trading, a decline of 18% from the average daily volume of 265,954 shares. The stock had previously closed at $22.33.

Wall Street Analysts Forecast Growth

Several brokerages have commented on DMRA. Evercore began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 target price for the company. UBS Group began coverage on Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price target on the stock. Wedbush initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, May 28th. They set an “outperform” rating and a $35.00 target price for the company. Guggenheim reiterated a “buy” rating and issued a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Finally, Royal Bank Of Canada initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They set an “outperform” rating and a $40.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Damora Therapeutics, Inc. Common Stock has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Damora Therapeutics, Inc. Common Stock Trading Down 5.2%

The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -3.79 and a beta of 1.46. The firm’s 50 day simple moving average is $25.06 and its two-hundred day simple moving average is $25.36.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). As a group, equities research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -1.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Several hedge funds have recently bought and sold shares of DMRA. Janus Henderson Group PLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $40,000. Virtu Financial LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at $49,000. Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $76,000. Connective Capital Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter valued at about $100,000. Finally, Geode Capital Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at about $266,000. 14.20% of the stock is owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.